Cone Rod Dystrophy Market Insights, Epidemiology Facts, Key Players, Therapies Report 2032

DelveInsight's Cone Rod Dystrophy Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Cone Rod Dystrophy market share of the individual therapies, current and forecasted Cone Rod Dystrophy market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Cone Rod Dystrophy Overview

Cone rod dystrophies (CRDs) are inherited retinal dystrophies that belong to the group of pigmentary retinopathies. CRDs are characterized by retinal pigment deposits visible on fundus examination, predominantly localized to the macular region. CRD is characterized by primary cone involvement, or, sometimes, by concomitant loss of both cones and rods that explains the predominant symptoms of CRDs.

Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Cone Rod Dystrophy Epidemiology Insights

Cone-rod dystrophy (CRD) is a group of related eye disorders that causes vision loss, which becomes more severe over time. According to National Institutes of Health (n.d.), CRD is estimated to affect 1 in 30,000 to 40,000 individuals.

Some of the key highlights of the Cone Rod Dystrophy Epidemiology Facts

According to Orphanet Journal of Rare Diseases, the estimated prevalence of CRDs is 1 in 40,000 in Europe. The four most commonly mutated genes are ABCA4 (1p22.1) responsible for 30 to 60% of autosomal recessive CRDs, CRX (19q13.33) and GUCY2D (17p13.1) responsible for many reported cases of autosomal dominant CRDs, and RPGR (Xp11.4) responsible for X-linked CRDs.

According to the study by Gill et al. (2019), inherited disorders of cone function are classically divided into two subtypes: stationary and progressive. Mutations in 32 genes are reported to cause CRD, among which identified genes are predominantly cause CRD and 22 that lead to CRD.

According to the National Organization for Rare Disorders (n.d.), Cone dystrophy affects males and females in equal numbers when it occurs sporadically or is inherited in an autosomal dominant or recessive pattern. The X-linked form of cone dystrophy only affects males fully, although some females may have mild symptoms of the disorder.

Cone Rod Dystrophy Epidemiology Segmentation in the 7MM [2019-2032]
Total Cone Rod Dystrophy Prevalent Cases
Cone Rod Dystrophy Inheritance-specific Cases
Cone Rod Dystrophy Diagnosed and treatable cases

Cone Rod Dystrophy Type-specific Cases
Learn more about report @ https://www.delveinsight.com/report-store/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Cone Rod Dystrophy Symptoms

Initial signs and symptoms that usually occur in childhood may include decreased sharpness of vision (visual acuity) and abnormal sensitivity to light (photophobia). These signs are usually followed by blind spots in the central field of vision (scotomas), loss of color perception, and loss of peripheral vision. Most individuals with this condition are legally blind by mid adulthood.

Cone Rod Dystrophy Forms

There are two main forms of cone dystrophy: stationary cone dystrophy and progressive cone dystrophy. In stationary cone dystrophy, symptoms tend to remain stable and are usually present at birth or early childhood. In progressive cone dystrophy, symptoms slowly worsen over time.

Cone Rod Dystrophy Types

There are more than 30 types of cone-rod dystrophy, which are distinguished by their genetic cause and their pattern of inheritance: autosomal recessive, autosomal dominant, and X-linked. Additionally, cone-rod dystrophy can occur alone without any other signs and symptoms or it can occur as part of a syndrome that affects multiple parts of the body.

Cone Rod Dystrophy Diagnosis

A diagnosis of CRD is made based on identification of characteristic symptoms, a detailed family history, and a thorough clinical evaluation involving ophthalmological exams that measure visual acuity, the ability to perceive color and field of vision. An electroretinogram (ERG) is used to confirm the diagnosis of cone dystrophy.

Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Cone Rod Dystrophy Treatment Market

With no proven treatments for Cone rod dystrophies (CRD) that halt progression or restore lost vision, the management of CRD aims at slowing down the degenerative process, treating the complications and helping patients to cope with the social and psychological impact of blindness and consists of symptomatic alleviation, including refractive correction, use of tinted spectacles/contact lenses for photophobia and low vision aids. Some ophthalmologists believe that treatment with high doses of Vitamin A can slow the progression. Patients with specific forms of CRDs can be advised to adopt strategies to try to slow degeneration, based on the knowledge of gene function or investigation of animal models.

Cone Rod Dystrophy Market Insights

The dynamics of the Cone rod dystrophie's market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. There are some positive candidates in the early, middle and late developmental stage.

Cone Rod Dystrophy Emerging Therapy Assessment
Key players, such as MeiraGTx, Applied Genetic Technologies Corp, and others are in the process of developing potential therapies for the treatment of Cone Dystrophy. The launch of emerging therapies is expected to significantly impact the treatment scenario of Cone rod dystrophies in the upcoming years.

Request for More Info @ https://www.delveinsight.com/report-store/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Cone Rod Dystrophy Companies includes-
MeiraGTx
Applied Genetic Technologies Corp, and others
Cone Rod Dystrophy Therapies
AGTC-501
AAV8-RPGR, and others

View Detailed Research Report Here @ https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Table of content
Key Insights
Executive Summary
Competitive Intelligence Analysis
Cone Rod Dystrophy: Market Overview at a Glance
Cone Rod Dystrophy: Disease Background and Overview
Patient Journey
Cone Rod Dystrophy Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Cone Rod Dystrophy Unmet Needs
Key Endpoints of Cone Rod Dystrophy Treatment
Marketed Products
Emerging Therapies
Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Consult with our Business Expert @ https://www.delveinsight.com/report-store/cone-rod-dystrophy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us
Yash
info@delveinsight.com
https://www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.